Showing results (1661-1670 of 1,870) with videos related to

Sort By:
Pageof 187
Science (New York, N.Y.)|October 31, 2024
Group 2 innate lymphoid cells promote inhibitory synapse development and social behaviorJerika J Barron, Nicholas M Mroz, Sunrae E Taloma, et al.
Journal of Neurophysiology|December 12, 2025
Microscale maps of bursting dynamics across human hippocampal slices from epilepsy patientsMatthew A T Elliott, John P Andrews, Tjitse van der Molen, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Molecular dynamics of Brodmann Area 22 in development and autismVarun Suresh, Emilie M Wigdor, Yuhan Hao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2019
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyYucai Wang, Umar Farooq, Brian K Link, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 1999
A new class of selective and potent inhibitors of neuronal nitric oxide synthaseJ A Lowe, W Qian, R A Volkmann, et al.
Rehabilitation Psychology|June 25, 2026
African American Dementia Caregiver Strategies Inventory: Initial descriptive and psychometric evaluationRobert L Glueckauf, Nik M Lampe, Benjamin J Behers, et al.
Nature Communications|January 8, 2015
Large resistivity modulation in mixed-phase metallic systemsYeonbae Lee, Z Q Liu, J T Heron, et al.
Neuron|January 26, 2021
Parallel in vivo analysis of large-effect autism genes implicates cortical neurogenesis and estrogen in risk and resilienceHelen Rankin Willsey, Cameron R T Exner, Yuxiao Xu, et al.
Annals of Hematology|May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphomaGrzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood|January 25, 2020
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agentAlberto Risueño, Patrick R Hagner, Fadi Towfic, et al.
Pageof 187